STA
GMAB icon

Summit Trail Advisors’s Genmab GMAB Stock Holding History

Summit Trail Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Sell
7,765
-183
-2% -$4.86K ﹤0.01% 1411
2026
Q1 		$213K Buy
+7,948
New +$238K ﹤0.01% 1364

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Summit Trail Advisors's GMAB Position: Q2 2026 in Review

Summit Trail Advisors reduced its Genmab (GMAB) stake by 2.3% in Q2 2026, selling an estimated $4.86K and leaving 7,765 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #1411.

Summit Trail Advisors first reported a position in GMAB in Q1 2026 and has held it in 2 quarters since. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Summit Trail Advisors held 7,765 shares of Genmab worth $213K as of Q2 2026.
  • Summit Trail Advisors sold 183 Genmab shares in Q2 2026, an estimated $4.86K.
  • Genmab made up ﹤0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1411 holding.
  • Summit Trail Advisors first reported a position in Genmab in Q1 2026 and has held it in 2 quarters since.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.